Patents Assigned to Rheinische Friedrich-Wilhelms-Universitat
  • Patent number: 11933009
    Abstract: The invention relates to a device for taking up oil from a water surface, comprising a container for receiving the oil and an oil-transporting means, wherein a portion of the oil-transporting means can be brought into fluid communication with the water surface and another portion of the oil-transporting means is disposed within the container, wherein the oil can be transported into the container via the oil-transporting means, wherein the oil-transporting means is formed from a hydrophobic fabric, the surface of which comprises filament-shaped and/or grid-like structures which are designed in such a way that they retain a gas layer on the surface of the hydrophobic fabric under water. The invention further relates to a corresponding method for taking up oil from a water surface.
    Type: Grant
    Filed: July 25, 2019
    Date of Patent: March 19, 2024
    Assignee: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    Inventors: Wilhelm Barthlott, Markus Moosmann, Matthias Mail
  • Publication number: 20240076680
    Abstract: The present invention relates to an aptamer not binding to the receptor-binding domain of the SARS-CoV-2 spike glycoprotein nor inhibiting the interaction of the receptor-binding domain (RED) of spike glycoprotein with angiotensin-converting enzyme II (ACE2) and/or comprising or consisting of a nucleotide sequence SEQ ID NO: 1, a composition comprising the aptamer, and the use of the aptamer in the detection of SARS-CoV-2 or diagnosis or treatment of a SARS-CoV-2 infection.
    Type: Application
    Filed: December 12, 2021
    Publication date: March 7, 2024
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    Inventors: Günter MAYER, Michael FAMULOK, Anton SCHMITZ, Anna Maria WEBER, Stefan BREUERS, Volkmar FIEBERG
  • Publication number: 20230358760
    Abstract: The present invention relates to an aptamer comprising a nucleotide sequence SEQ ID NO: 1, preferably comprising or consisting of a nucleotide sequence SEQ ID NO: 4-6. The invention further relates to a composition comprising the aptamer, and the use of the aptamer as a medicament or a diagnostic reagent, particularly for use in the detection or diagnosing of a rejection of a renal allograft.
    Type: Application
    Filed: August 31, 2021
    Publication date: November 9, 2023
    Applicants: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN, LEIBNIZ UNIVERSITÄT HANNOVER
    Inventors: Günter MAYER, Julia SIEGL, Cornelia BLUME, Linh PHUNG
  • Publication number: 20230181522
    Abstract: The present invention relates to a solid or liquisolid formulation comprising corallopyronin A, wherein the formulation comprises an amorphous solid dispersion of corallopyronin A embedded in a water-soluble polymer or corallopyronin A loaded onto porous silica.
    Type: Application
    Filed: April 29, 2021
    Publication date: June 15, 2023
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    Inventors: Karl G. WAGNER, Anna Katharina KROME, Achim HÖRAUF, Gabriele M. KÖNIG, Kenneth Michael PFARR, Andrea SCHIEFER, Stefan KEHRAUS, Marc Peter HÜBNER
  • Publication number: 20230165879
    Abstract: The present invention relates to a liquisolid pharmaceutical formulation comprising a porous carrier and an active pharmaceutical ingredient loaded onto a surface of the porous carrier, wherein the active pharmaceutical ingredient is dispersed in propylene carbonate or a mixture of propylene carbonate and a further solvent and the dispersion of the active pharmaceutical ingredient and propylene carbonate or a mixture of propylene carbonate and a further solvent is loaded onto the external surface and the internal surface located inside the pores of the porous carrier thereby forming a liquisolid system, and to a process for manufacturing such a liquisolid pharmaceutical formulation.
    Type: Application
    Filed: April 29, 2021
    Publication date: June 1, 2023
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    Inventors: Karl G. WAGNER, Alf LAMPRECHT, Anna Katharina KROME, Daris GRISIC, Alexander DENNINGER, Tim BECKER
  • Patent number: 11649502
    Abstract: The present invention relates to methods for detecting activation of a brown/beige fat cell or brown/beige adipose tissue (BAT) in a biological sample taken from a mammal to be diagnosed, comprising measuring the amount of miR-92 in said sample. The invention furthermore relates to diagnostic and clinical applications of the methods of the invention.
    Type: Grant
    Filed: September 18, 2020
    Date of Patent: May 16, 2023
    Assignees: Rheinische Friedrich-Wilhelms-Universität Bonn, Maastricht University
    Inventors: Alexander Pfeifer, Joschka Buyel, Yong Chen, Wouter Van Marken Lichtenbelt
  • Patent number: 11291675
    Abstract: The present invention relates to 6?-sialyllactose and/or pharmaceutically acceptable salts thereof for use in the treatment of a disease selected from hearing loss and hearing loss—associated tinnitus.
    Type: Grant
    Filed: December 7, 2018
    Date of Patent: April 5, 2022
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Harald Neumann, Christine Klaus, Anahita Shahraz
  • Publication number: 20220073921
    Abstract: The present invention relates to an aptamer comprising a nucleotide sequence SEQ ID NO: 1 or a fragment thereof of at least 20 contiguous nucleotides of the nucleotide sequence SEQ ID NO: 2, wherein the aptamer comprises a polyethylene glycol (PEG) moiety conjugated to the 5? or the 3? end. The invention further relates to a composition comprising the aptamer, and the use of the aptamer in the diagnosis and treatment of cancer, particularly hormone refractory prostate tumours.
    Type: Application
    Filed: January 20, 2020
    Publication date: March 10, 2022
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    Inventors: Frédéric DUCONGÉ, Andreas LINGNAU, Holger WEBER, Michael KUBBUTAT, Günter MAYER
  • Publication number: 20220056402
    Abstract: A method for producing induced photoreceptor cells from an initial cell is provided, the method includes providing one or more transcription factors (TFs) including at least GON4L to the initial cell. In some versions, the initial cell is a human induced pluripotent stem cell (iPSC). In other embodiments the method includes providing the TFs OTX2 and/or NEUROD1 to the initial cell. Cells produced and obtainable by the method are also provided, the use of these cells as a medicament in the treatment of retinopathy, vectors for inducing the photoreceptor cells and combinations of transcription factors intended for this use.
    Type: Application
    Filed: March 2, 2020
    Publication date: February 24, 2022
    Applicant: Rheinische Friedrich-Wilhelms-Universitat Bonn
    Inventors: Volker Busskamp, Marta Zuzic, Anka Kempe
  • Patent number: 11142763
    Abstract: The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.
    Type: Grant
    Filed: May 2, 2018
    Date of Patent: October 12, 2021
    Assignee: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    Inventors: Marion Goldeck, Jasper Van Den Boorn, János Ludwig, Christine Schuberth-Wagner
  • Publication number: 20210310004
    Abstract: The invention relates to a method of identifying or producing an aptamer, the method comprising the steps of: a) Providing a candidate mixture of nucleic acids; b) Contacting the candidate mixture with a target sample; c) Partitioning nucleic acids that bind to the target sample from those that do not bind; d) Amplifying the binding nucleic acids to produce a population of nucleic acids that bind the target sample; e) Single strand displacement of the amplified nucleic acids, f) optionally repeating the steps a) to e), thereby identifying or producing an aptamer, wherein the target sample provides one or more peptides and/or proteins in a denatured form.
    Type: Application
    Filed: July 29, 2019
    Publication date: October 7, 2021
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    Inventors: Günter MAYER, Nora KARNOWSKI, Maren HAMANN, Tjasa LEGEN
  • Publication number: 20210238818
    Abstract: The invention relates to a device for taking up oil from a water surface, comprising a container for receiving the oil and an oil-transporting means, wherein a portion of the oil-transporting means can be brought into fluid communication with the water surface and another portion of the oil-transporting means is disposed within the container, wherein the oil can be transported into the container via the oil-transporting means, wherein the oil-transporting means is formed from a hydrophobic fabric, the surface of which comprises filament-shaped and/or grid-like structures which are designed in such a way that they retain a gas layer on the surface of the hydrophobic fabric under water. The invention further relates to a corresponding method for taking up oil from a water surface.
    Type: Application
    Filed: July 25, 2019
    Publication date: August 5, 2021
    Applicant: RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITÄT BONN
    Inventors: Wilhelm BARTHLOTT, Markus MOOSMANN, Matthias MAIL
  • Publication number: 20210147847
    Abstract: Compositions comprising aptamers, and methods of thereof as carrier molecules in cell-mediated immunotherapies, and activation of antigen-specific T-cell responses.
    Type: Application
    Filed: March 30, 2019
    Publication date: May 20, 2021
    Applicant: Rheinische Friedrich-Wilhelms-Universitat Bonn
    Inventors: Silvana HASSEL, Gunter MAYER, Sven BURGDORF
  • Publication number: 20200289537
    Abstract: The present invention relates to 6?-sialyllactose and/or pharmaceutically acceptable salts thereof for use in the treatment of a disease selected from hearing loss and hearing loss—associated tinnitus.
    Type: Application
    Filed: December 7, 2018
    Publication date: September 17, 2020
    Applicant: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Harald NEUMANN, Christine KLAUS
  • Publication number: 20200208184
    Abstract: A method of producing 5-ketofructose using an acetic acid bacterium which is genetically modified to express a fructose dehydrogenase as well as to microorganisms which can be used in said method.
    Type: Application
    Filed: June 13, 2018
    Publication date: July 2, 2020
    Applicants: RWTH Aachen, Forschungszentrum Jülich GmbH, Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Elena Herweg, Jochen Büchs, Michael Bott, Ines Kiefler, Uwe Deppenmeier, Konrad Kosciow, Anna Siemen
  • Publication number: 20200197300
    Abstract: The present invention provides a formulation of Coenzyme Q10 that can be re-dispersed from a stable dry powder to formulation to yield a nanodispersion that can be readily aerosolized for inhalation.
    Type: Application
    Filed: January 30, 2020
    Publication date: June 25, 2020
    Applicants: STC.UNM, RHEINISCHE FRIEDRICH-WILHELMS-UNIVERSITAT BONN, BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Jason Thomas McConville, Thiago Cardoso Carvalho, Kristina Schönhoff
  • Publication number: 20200123547
    Abstract: The present invention relates to a nucleic acid-based assembly comprising: at least one nucleic acid aptamer, and at least one nucleic acid motif designed to physically capture a drug. The nucleic acid motif may comprise one or more photo-responsive moieties that effect the release of the drug upon irradiation. The aptamer and the nucleic acid motif each can be covalently linked to one or more lipids, and the lipid-modified aptamer and nucleic acid motif may form the assembly through noncovalent interaction. The invention further relates to use of the nucleic acid-based assembly in the treatment of cancer.
    Type: Application
    Filed: December 7, 2017
    Publication date: April 23, 2020
    Applicant: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Michael FAMULOK, Deepak PRUSTY, Adam VOLKER, Stephan IRSEN
  • Patent number: 10551388
    Abstract: The present invention relates to a method of determining a protein in a sample and the use of the method for the identification of aptamer target proteins.
    Type: Grant
    Filed: January 15, 2018
    Date of Patent: February 4, 2020
    Assignee: Rheinische Friedrich-Wilhelms-Universitat Bonn
    Inventors: Michael Famulok, Gunter Mayer, Jan Vinkenborg
  • Patent number: 10238682
    Abstract: Oligonucleotides bearing free, uncapped 5? phosphate group(s) are recognized by RIG-I, leading to the induction of type I IFN, IL-18 and IL-1? production. Bacterial RNA also induces type I IFN production. 5? phosphate oligonucleotides and bacterial RNA can be used for inducing an anti-viral response or an anti-bacterial response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in vitro and in vivo and for treating various disorders and diseases such as viral infections, bacterial infections, parasitic infections, tumors, allergies, autoimmune diseases, immunodeficiencies and immunosuppression. Single-stranded 5? triphosphate RNA can be used for inducing an anti-viral response, an anti-bacterial response, or an anti-tumor response, in particular, type I IFN and/or IL-18 and/or IL-1? production, in a target cell-specific manner.
    Type: Grant
    Filed: November 9, 2015
    Date of Patent: March 26, 2019
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Gunther Hartmann, Veit Hornung
  • Patent number: 10196638
    Abstract: The present invention provides an oligonucleotide which is capable of activating RIG-I and inducing an anti-viral, in particular, an IFN, response in cells expressing RIG-I. The present invention further provides an oligonucleotide which is capable of activating RIG-I and which has target gene-silencing activity. The oligonucleotide of the present invention has a double-stranded section of at least 19, preferably at least 21 bp, at least one 5? triphosphate, and at least one blunt end which bears a 5? triphosphate. The present invention further provides the use said oligonucleotide for inducing an anti-viral, in particular, an IFN, response in vitro and in vivo. The present invention additionally provides the use of said oligonucleotide for preventing and/or treating diseases or conditions such as infections, tumors/cancers, and immune disorders.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: February 5, 2019
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Gunther Hartmann, Martin Schlee